In one paragraphArticle in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Yin ChenDepartment of Neurology, NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0009-0006-2324-5029 Wei TangDepartment of Neurology, NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0009-0007-5609-5220 Chi LiuDepartment of Neurology, NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0009-0004-7181-3620 Hailin WuDepartment of Neurology, NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0009-0009-2993-2059 Ning WangDepartment of Neurology, NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0009-0009-5887-7204 Yiyun LiuDepartment of Neurology, NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0000-0001-7079-7025 Dongfang WangDepartment of Neurology, NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0000-0002-7517-3972 Siwen GuiDepartment of Neurology, NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0000-0002-6169-5817 Xiaogang ZhongDepartment of Neurology, NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0000-0002-6648-4461 Bin HuaDepartment of Neurology, NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0000-0002-2650-1220 Lining YangDepartment of Rehabilitation Medicine, Key Laboratory of Physical Medicine and Precision Rehabilitation of Chongqing Municipal Health Commission, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0000-0001-6120-7214 Juncai PuDepartment of Neurology, NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0000-0001-9841-0291 Peng XieDepartment of Neurology, NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0000-0002-0081-6048 Funding
National Natural Science Foundation of China 82371526National Natural Science Foundation of China W2511089Natural Science Foundation of Chongqing CSTB2024NSCQ-MSX1027Natural Science Foundation of Chongqing CSTB2024NSCQ-QCXMX0033The Chongqing Medical Science and Technology Innovation Four Centers Construction Project - Chongqing Clinical Evaluation and Research Center for Cardiovascular and Cerebrovascular Drug and Devices (Materials) ProjectThe Chongqing Science and Health Joint Medical Research Youth Project 2023QNXM035The Chongqing Technology Innovation and Application Development key project CSTB2024TIAD-KPX0035The Fund of Moutaintop plan project in the First Affiliated Hospital of Chongqing Medical University cyyy-xkdfjh-lcyj-202301The Joint project of Chongqing Municipal Science and Technology Bureau and Chongqing Health Commission 2023CCXM003
6 · The paper itselfAbstract
Fluoxetine is a widely used antidepressant, yet integrated analyses of its molecular mechanism remain limited. This study systematically investigated potential molecular mechanisms underlying the antidepressant effects of fluoxetine by integrating these scattered data. Using the ProMENDA database, we identified metabolites and proteins altered by fluoxetine in the brain of animal models of depression. We curated 273 differentially expressed metabolite entries and 791 differentially expressed protein entries from fluoxetine treatment and performed vote-counting, pathway enrichment, pathway crosstalk and drug-associated metabolite set enrichment analyses. Vote-counting analysis showed altered neurotransmitter levels, including increased levels of monoamines and decreased levels of neurotoxic quinolinic acid and glutamate. The results of pathway analyses based on both altered metabolites and proteins showed 121 significantly enriched pathways. Pathway crosstalk analysis identified four pathway-based modules, which were mainly involved in amino acid metabolism, neurotransmitters and multiple biological processes. Drug-associated metabolite set enrichment analysis revealed 76 significantly enriched drug-related pathways, which were mainly involved in antidepressants. This study provides a comprehensive understanding of the antidepressant effects of fluoxetine, which may provide insights for the development of novel antidepressants.
Indexed as
DepressionFluoxetineMetabolomeMetabolomicsProteomicsAnimalsAntidepressive AgentsBrainDisease Models, AnimalMiceAntidepressive AgentsFluoxetineantidepressantfluoxetinemetabolomicsproteomics
Identifiers
PMID41880109
PMCPMC13098112
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390